Daxor Corporation (DXR) - Total Assets
Based on the latest financial reports, Daxor Corporation (DXR) holds total assets worth $35.90 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Daxor Corporation - Total Assets Trend (1985–2024)
This chart illustrates how Daxor Corporation's total assets have evolved over time, based on quarterly financial data. Also see Daxor Corporation (DXR) market capitalisation for the company's overall valuation and market capitalisation.
Daxor Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Daxor Corporation's total assets of $35.90 Million consist of 0.1% current assets and 100.0% non-current assets. Review Daxor Corporation total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $9.68K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1985–2024)
This chart illustrates how Daxor Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Daxor Corporation (DXR) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Daxor Corporation's current assets represent 0.1% of total assets in 2024, a decrease from 97.1% in 1985.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 95.4% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1985.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Daxor Corporation Competitors by Total Assets
Key competitors of Daxor Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Tinavi Medical Technologies Co Ltd
SHG:688277
|
China | CN¥1.64 Billion |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK
|
Indonesia | Rp980.33 Billion |
|
Interojo Inc
KQ:119610
|
Korea | ₩252.22 Billion |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
Daxor Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.17 | 0.25 | 0.42 |
| Quick Ratio | 0.17 | 0.25 | 0.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-91.76K | $-77.22K | $-46.01K |
Daxor Corporation - Advanced Valuation Insights
This section examines the relationship between Daxor Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.02 |
| Latest Market Cap to Assets Ratio | 1.85 |
| Asset Growth Rate (YoY) | 5.1% |
| Total Assets | $36.63 Million |
| Market Capitalization | $67.77 Million USD |
Valuation Analysis
Above Book Valuation: The market values Daxor Corporation's assets above their book value (1.85x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Daxor Corporation's assets grew by 5.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Daxor Corporation (1985–2024)
The table below shows the annual total assets of Daxor Corporation from 1985 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $36.63 Million | +5.06% |
| 2023-12-31 | $34.87 Million | +15.23% |
| 2022-12-31 | $30.26 Million | +21.13% |
| 2021-12-31 | $24.98 Million | +50.92% |
| 2020-12-31 | $16.55 Million | +16.56% |
| 2019-12-31 | $14.20 Million | -19.43% |
| 2018-12-31 | $17.63 Million | -8.72% |
| 2017-12-31 | $19.31 Million | -6.37% |
| 2016-12-31 | $20.62 Million | -1.29% |
| 2015-12-31 | $20.89 Million | -54.63% |
| 2014-12-31 | $46.05 Million | -2.84% |
| 2013-12-31 | $47.39 Million | -15.86% |
| 2012-12-31 | $56.33 Million | -34.29% |
| 2011-12-31 | $85.72 Million | -6.00% |
| 2010-12-31 | $91.20 Million | +21.29% |
| 2009-12-31 | $75.19 Million | -2.13% |
| 2008-12-31 | $76.82 Million | -25.09% |
| 2007-12-31 | $102.56 Million | +31.21% |
| 2006-12-31 | $78.17 Million | +31.23% |
| 2005-12-31 | $59.57 Million | +6.50% |
| 2004-12-31 | $55.93 Million | +15.79% |
| 2003-12-31 | $48.30 Million | +16.18% |
| 2002-12-31 | $41.57 Million | -4.52% |
| 2001-12-31 | $43.54 Million | -12.17% |
| 2000-12-31 | $49.58 Million | +38.30% |
| 1999-12-31 | $35.85 Million | -18.72% |
| 1998-12-31 | $44.10 Million | +6.78% |
| 1997-12-31 | $41.30 Million | +10.72% |
| 1996-12-31 | $37.30 Million | -1.06% |
| 1995-12-31 | $37.70 Million | +7.71% |
| 1994-12-31 | $35.00 Million | +20.27% |
| 1993-12-31 | $29.10 Million | -10.74% |
| 1992-12-31 | $32.60 Million | +11.64% |
| 1991-12-31 | $29.20 Million | -9.03% |
| 1990-12-31 | $32.10 Million | +21.13% |
| 1989-12-31 | $26.50 Million | -12.54% |
| 1988-12-31 | $30.30 Million | +25.73% |
| 1987-12-31 | $24.10 Million | +13.15% |
| 1986-12-31 | $21.30 Million | +21.71% |
| 1985-12-31 | $17.50 Million | -- |
About Daxor Corporation
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corpo… Read more